TG Therapeutics 2024年第四季度GAAP每股收益$0.15,与预期一致,销售额$108.19M超$99.95M预期

财报速递
03 Mar
TG Therapeutics(纳斯达克股票代码:TGTX)公布季度每股收益为$0.15,符合分析师的一致预期。与去年同期每股亏损$(0.10)相比,这是一个250%的增长。公司本季度销售额为$108.19百万,超过分析师预期的$99.95百万,超出8.24%。与去年同期的$43.97百万销售额相比,这是一个146.04%的增长。

以上内容来自Benzinga Earnings专栏,原文如下:

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. This is a 250 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $108.19 million which beat the analyst consensus estimate of $99.95 million by 8.24 percent. This is a 146.04 percent increase over sales of $43.97 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10